The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
Subscribe To Our Newsletter & Stay Updated
